Keene & Associates Inc. increased its holdings in shares of Medtronic plc (NYSE:MDT – Free Report) by 0.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,941 shares of the medical technology company’s stock after buying an additional 127 shares during the period. Medtronic comprises 2.7% of Keene & Associates Inc.’s investment portfolio, making the stock its 19th largest holding. Keene & Associates Inc.’s holdings in Medtronic were worth $3,506,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the business. M&G Plc acquired a new stake in shares of Medtronic in the first quarter valued at $259,160,000. Capital Research Global Investors increased its holdings in Medtronic by 7.1% during the 1st quarter. Capital Research Global Investors now owns 30,884,412 shares of the medical technology company’s stock worth $2,691,577,000 after purchasing an additional 2,044,109 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its position in Medtronic by 1,195.9% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,837,600 shares of the medical technology company’s stock valued at $144,637,000 after purchasing an additional 1,695,800 shares in the last quarter. International Assets Investment Management LLC boosted its stake in shares of Medtronic by 8,908.6% in the 3rd quarter. International Assets Investment Management LLC now owns 1,298,415 shares of the medical technology company’s stock valued at $116,896,000 after buying an additional 1,284,002 shares during the period. Finally, Troy Asset Management Ltd acquired a new position in shares of Medtronic during the second quarter worth about $85,440,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages recently weighed in on MDT. Wells Fargo & Company raised their target price on shares of Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Robert W. Baird lifted their price objective on shares of Medtronic from $82.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Truist Financial increased their target price on Medtronic from $90.00 to $93.00 and gave the company a “hold” rating in a report on Monday, October 14th. Daiwa America raised Medtronic to a “strong-buy” rating in a report on Friday, August 23rd. Finally, Royal Bank of Canada upgraded Medtronic from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $98.00 to $105.00 in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $95.36.
Medtronic Price Performance
Shares of NYSE MDT opened at $92.27 on Thursday. The company has a current ratio of 2.13, a quick ratio of 1.61 and a debt-to-equity ratio of 0.55. The stock has a market cap of $118.32 billion, a P/E ratio of 33.55, a P/E/G ratio of 2.53 and a beta of 0.84. The stock has a 50 day moving average of $89.04 and a two-hundred day moving average of $83.74. Medtronic plc has a twelve month low of $68.84 and a twelve month high of $92.39.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The firm had revenue of $7.97 billion during the quarter, compared to analysts’ expectations of $7.90 billion. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. Medtronic’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.20 EPS. On average, research analysts forecast that Medtronic plc will post 5.44 earnings per share for the current year.
Medtronic Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic’s dividend payout ratio is presently 101.82%.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More
- Five stocks we like better than Medtronic
- Insider Selling Explained: Can it Inform Your Investing Choices?
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- 3 Warren Buffett Stocks to Buy Now
- 3 Undervalued Technology Stocks With Big Rebound Potential
- What is Put Option Volume?
- NextEra Energy’s Strong Quarter Catches Wall Street’s Eye
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.